自体和异体干细胞移植治疗原始浆细胞样树突细胞肿瘤的长期生存。
Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm.
机构信息
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Hematology and Oncology.
Department of Medical Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan;
出版信息
Blood. 2015 Jun 4;125(23):3559-62. doi: 10.1182/blood-2015-01-621268. Epub 2015 Apr 27.
We sought to clarify the role of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN). We retrospectively identified 25 BPDCN patients (allo-HSCT, n = 14; auto-HSCT, n = 11) from registry data of the Japan Society for Hematopoietic Cell Transplantation and analyzed clinicopathologic data and clinical outcomes after transplantation. The median age at HSCT was 58 years (range, 17-67 years). All 11 patients who underwent auto-HSCT were in the first complete remission (CR1). With a median follow-up of 53.5 months, the overall survival rates at 4 years for patients who underwent auto-HSCT and allo-HSCT were 82% and 53% (P = .11), respectively, and progression-free survival rates were 73% and 48% (P = .14), respectively. Auto-HSCT for BPDCN in CR1 appears to provide promising results and deserves further evaluation in the setting of prospective trials.
我们旨在阐明高剂量化疗后自体造血干细胞移植（auto-HSCT）和异基因造血干细胞移植（allo-HSCT）在治疗原始浆细胞样树突细胞肿瘤（BPDCN）中的作用。我们从日本造血细胞移植学会的登记数据中回顾性地确定了 25 例 BPDCN 患者（allo-HSCT，n=14；auto-HSCT，n=11），并分析了移植后的临床病理数据和临床结果。HSCT 时的中位年龄为 58 岁（范围，17-67 岁）。接受 auto-HSCT 的 11 例患者均处于首次完全缓解（CR1）。中位随访 53.5 个月后，接受 auto-HSCT 和 allo-HSCT 的患者的 4 年总生存率分别为 82%和 53%（P=.11），无进展生存率分别为 73%和 48%（P=.14）。CR1 期 BPDCN 的 auto-HSCT 似乎提供了有希望的结果，值得在前瞻性试验中进一步评估。
Zotero 插件